Enhancement of semustine-induced cytotoxicity by chlorpromazine and caffeine in a human melanoma xenograft.
Chlorpromazine (CPZ) and caffeine (CFN) enhance the cytotoxicity of nitrosoureas in conventional murine tumor systems, but this effect was not confirmed in a randomized clinical trial which compared the action of semustine (MeCCNU) against the combination of MeCCNU, CPZ, and CFN. Since differences in repair systems are known to exist between cells of human or murine origin, we have employed a human melanoma xenograft system to quantify the drug interaction. The enhancement in human melanoma cells was similar to that observed with conventional murine tumor systems. Alkaline elution studies and determination of radioactivity from labeled MeCCNU pointed to increased drug retention and fixation of DNA damage as the mechanism of enhancement. Although toxicity studies were limited to murine tissues, there was evidence of increased toxicity, especially if MeCCNU was combined with both CPZ and CFN. Thus, a true therapeutic synergism may not be present for the combination. Some explanations for the failure to detect such drug interaction in clinical trials and the relevance of advanced preclinical tumor systems are discussed.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D001853:Bone Marrow / Q000187:drug effects / Q000378:metabolism; D002110:Caffeine / Q000008:administration & dosage; D002746:Chlorpromazine / Q000008:administration & dosage; D004249:DNA Damage; D004357:Drug Synergism; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012673:Semustine / Q000008:administration & dosage / Q000627:therapeutic use*; D014018:Tissue Distribution
D009607:Nitrosourea Compounds; D012673:Semustine; D002110:Caffeine; D002746:Chlorpromazine